腱鞘炎治療薬の世界市場レポート 2025年

腱鞘炎治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.0％で17億5,000万米ドルに成長します。予測期間中の成長は、遠隔医療サービスの拡大、世界ヘルスイニシアチブ、筋骨格系障害の有病率の上昇、腱鞘炎治療薬の需要拡大、慢性疾患の有病率の上昇に起因しています。主な発展動向としては、手術手技の進歩、手術におけるロボット工学の統合、低侵襲手術の進歩、ナノテクノロジーの革新、薬剤製剤の開発などが挙げられます。

筋骨格系疾患の有病率の上昇は、腱鞘炎治療薬市場の成長を大きく促進すると予想されます。筋、腱、靭帯、神経、関節に影響を及ぼす筋骨格系障害は、痛みを引き起こし、動きを妨げます。人口の高齢化、座りがちなライフスタイル、職業上の危険性の増加などの要因が、これらの障害の有病率の増加に寄与しています。腱鞘炎は、腱とその腱鞘の炎症を特徴とする疾患で、炎症を抑え痛みを緩和する抗炎症薬や副腎皮質ステロイドなどの薬物で治療されます。例えば、2023年3月にOffice for Health Improvement and Disparitiesが報告したところによると、英国では16歳以上の17.6％が長期の筋骨格系疾患を有しており、2021年の17.0％から増加しています。このような筋骨格系疾患の増加は、腱鞘炎治療薬に対する需要の増加に寄与しています。

スポーツ傷害の発生率の増加も、腱鞘炎治療薬市場における効果的な治療薬の需要を促進しています。スポーツ傷害は、軽度の捻挫から重度の骨折まで、多くの場合、運動中の使い過ぎ、不適切な技術、衝突が原因となっています。腱鞘炎治療薬は、痛みや腫れを和らげ、回復を早め、運動能力を向上させることで、これらの傷害を治療するために使用されます。例えば、Howden Group Holdings Ltd.が2023年11月に発表した報告書では、FIFAワールドカップ・カタール2022の開催後、足首の怪我が170％増加、ふくらはぎ/脛の怪我が200％増加、ハムストリングの怪我が130％増加するなど、イングランド・プレミアリーグにおけるスポーツ傷害の大幅な急増が強調されています。スポーツ関連傷害の増加により、腱鞘炎治療薬の需要が高まっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界腱鞘炎治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の腱鞘炎治療薬市場：成長率分析
• 世界の腱鞘炎治療薬市場の実績：規模と成長, 2019-2024
• 世界の腱鞘炎治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界腱鞘炎治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の腱鞘炎治療薬市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非ステロイド性抗炎症薬（NSAID）
• コルチコステロイド
• 抗生物質
• その他の薬物の種類
• 世界の腱鞘炎治療薬市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ドケルバン腱鞘炎
• 狭窄性腱鞘炎
• トリガーフィンガー
• その他の適応症
• 世界の腱鞘炎治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• トピック
• 世界の腱鞘炎治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の腱鞘炎治療薬市場非ステロイド性抗炎症薬（NSAIDs）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• イブプロフェン
• ナプロキセン
• ジクロフェナク
• セレコキシブ
• 世界の腱鞘炎治療薬市場コルチコステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プレドニゾン
• メチルプレドニゾロン
• デキサメタゾン
• トリアムシノロン
• 世界の腱鞘炎治療薬市場抗生物質の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ペニシリン
• セファロスポリン
• フルオロキノロン
• マクロライド
• 世界の腱鞘炎治療薬市場、その他の薬剤タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 疾患修飾性抗リウマチ薬（DMARD）
• 生物学的製剤
• 鎮痛剤

第7章 地域別・国別分析

• 世界の腱鞘炎治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の腱鞘炎治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 腱鞘炎治療薬市場：競合情勢
• 腱鞘炎治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GSK plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Perrigo Company plc
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Aurobindo Pharma Limited
• Endo International plc
• Lupin Limited
• Mallinckrodt Pharmaceuticals
• Zydus Cadila Healthcare
• AdvaCare Pharma

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 腱鞘炎治療薬市場2029：新たな機会を提供する国
• 腱鞘炎治療薬市場2029：新たな機会を提供するセグメント
• 腱鞘炎治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Tenosynovitis drugs are medications used to alleviate inflammation, pain, and swelling in the tendon sheath caused by conditions such as infection, overuse, or autoimmune diseases. Treatment options typically include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and antibiotics for infectious cases. In severe or chronic inflammatory forms, disease-modifying antirheumatic drugs (DMARDs) or biologics may be prescribed.

The main drug types in the tenosynovitis drug market include NSAIDs, corticosteroids, antibiotics, and other medications. NSAIDs are commonly used to reduce pain and inflammation without steroids, helping manage tenosynovitis symptoms such as swelling and discomfort. These drugs are indicated for conditions such as De Quervain tenosynovitis, stenosing tenosynovitis, and trigger finger. They are available in various administration forms, including oral, injectable, and topical, and are distributed through hospital pharmacies, retail pharmacies, and online platforms.

The tenosynovitis drugs market research report is one of a series of new reports from The Business Research Company that provides tenosynovitis drugs market statistics, including the tenosynovitis drugs industry's global market size, regional shares, competitors with a tenosynovitis drugs market share, detailed tenosynovitis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the tenosynovitis drugs industry. This tenosynovitis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tenosynovitis drugs market size has grown strongly in recent years. It will grow from $1.19 billion in 2024 to $1.29 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth during the historic period can be attributed to the rise in sport injuries, the growing aging population, increased healthcare expenditure, greater awareness about tenosynovitis, and the increasing adoption of biologic treatments.

The tenosynovitis drugs market size is expected to see strong growth in the next few years. It will grow to $1.75 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth during the forecast period can be attributed to the expansion of telehealth services, global health initiatives, the rising prevalence of musculoskeletal disorders, growing demand for tenosynovitis drugs, and the increasing prevalence of chronic diseases. Key trends include advancements in surgical techniques, the integration of robotics in surgery, progress in minimally invasive procedures, innovations in nanotechnology, and developments in drug formulation.

The rising prevalence of musculoskeletal disorders is expected to significantly drive the growth of the tenosynovitis drugs market. Musculoskeletal disorders, which affect muscles, tendons, ligaments, nerves, and joints, cause pain and hinder movement. Factors such as aging populations, sedentary lifestyles, and increased occupational hazards contribute to the growing prevalence of these disorders. Tenosynovitis, a condition characterized by inflammation of the tendons and their sheaths, is treated with medications such as anti-inflammatory drugs and corticosteroids that reduce inflammation and alleviate pain. For example, in March 2023, the Office for Health Improvement and Disparities reported that 17.6% of individuals aged 16 and older in the UK had a long-term musculoskeletal condition, up from 17.0% in 2021. This increase in musculoskeletal conditions is contributing to the growing demand for tenosynovitis drugs.

The growing incidence of sports injuries is also fueling the demand for effective therapeutics in the tenosynovitis drugs market. Sports injuries, which can range from minor sprains to more severe fractures, often result from overuse, improper technique, or collisions during athletic activities. These injuries commonly involve tendon inflammation, and tenosynovitis drugs are used to treat them by reducing pain and swelling, thus facilitating faster recovery and improved mobility. For instance, a report by Howden Group Holdings Ltd. in November 2023 highlighted a significant surge in sports injuries in the English Premier League, including a 170% increase in ankle injuries, a 200% rise in calf/shin injuries, and a 130% increase in hamstring injuries following the FIFA World Cup Qatar 2022. The higher incidence of sports-related injuries is driving greater demand for tenosynovitis drugs.

Companies in the tenosynovitis drugs market are also innovating with advanced drug formulations to enhance treatment efficacy, minimize side effects, and improve patient adherence. For instance, in July 2024, ANI Pharmaceuticals Inc. received FDA approval for its Naproxen delayed-release tablets, which were introduced as a generic alternative to EC-Naprosyn. This formulation helps provide extended pain relief while reducing gastrointestinal irritation, making it an ideal treatment for inflammatory conditions such as tenosynovitis, tendonitis, and arthritis. These innovations in drug formulation are improving the overall treatment experience, which is expected to further drive market growth.

Major players in the tenosynovitis drugs market are Pfizer Inc., Roche Holding AG, Bayer AG, Sanofi S.A., AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Cipla Limited, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Endo International plc, Lupin Limited, Mallinckrodt Pharmaceuticals, Zydus Cadila Healthcare, and AdvaCare Pharma.

North America was the largest region in the tenosynovitis drugs market in 2024. The regions covered in tenosynovitis drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tenosynovitis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tenosynovitis drugs market includes revenues earned by prescription medications, over-the-counter (OTC) products, biologics and disease-modifying drugs, topical treatments, injections, and infusions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tenosynovitis Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tenosynovitis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tenosynovitis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tenosynovitis drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS); Corticosteroids; Antibiotics; Other Drug Types
• 2) By Indication: De Quervain Tenosynovitis; Stenosing Tenosynovitis; Trigger Finger; Other Indications
• 3) By Route Of Administration: Oral; Injectable; Topical
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen; Naproxen; Diclofenac; Celecoxib
• 2) By Corticosteroids: Prednisone; Methylprednisolone; Dexamethasone; Triamcinolone
• 3) By Antibiotics: Penicillins; Cephalosporins; Fluoroquinolones; Macrolides
• 4) By Other Drug Types: Disease-Modifying Anti-Rheumatic Drugs (DMARDs); Biologics; Analgesics
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; Bayer AG; Sanofi S.A.; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Tenosynovitis Drugs Market Characteristics

3. Tenosynovitis Drugs Market Trends And Strategies

4. Tenosynovitis Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Tenosynovitis Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Tenosynovitis Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Tenosynovitis Drugs Market Growth Rate Analysis
• 5.4. Global Tenosynovitis Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Tenosynovitis Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Tenosynovitis Drugs Total Addressable Market (TAM)

6. Tenosynovitis Drugs Market Segmentation

• 6.1. Global Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
• Corticosteroids
• Antibiotics
• Other Drug Types
• 6.2. Global Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• De Quervain Tenosynovitis
• Stenosing Tenosynovitis
• Trigger Finger
• Other Indications
• 6.3. Global Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Topical
• 6.4. Global Tenosynovitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Tenosynovitis Drugs Market, Sub-Segmentation Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ibuprofen
• Naproxen
• Diclofenac
• Celecoxib
• 6.6. Global Tenosynovitis Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prednisone
• Methylprednisolone
• Dexamethasone
• Triamcinolone
• 6.7. Global Tenosynovitis Drugs Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Penicillins
• Cephalosporins
• Fluoroquinolones
• Macrolides
• 6.8. Global Tenosynovitis Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
• Biologics
• Analgesics

7. Tenosynovitis Drugs Market Regional And Country Analysis

• 7.1. Global Tenosynovitis Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Tenosynovitis Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Tenosynovitis Drugs Market

• 8.1. Asia-Pacific Tenosynovitis Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Tenosynovitis Drugs Market

• 9.1. China Tenosynovitis Drugs Market Overview
• 9.2. China Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Tenosynovitis Drugs Market

• 10.1. India Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Tenosynovitis Drugs Market

• 11.1. Japan Tenosynovitis Drugs Market Overview
• 11.2. Japan Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Tenosynovitis Drugs Market

• 12.1. Australia Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Tenosynovitis Drugs Market

• 13.1. Indonesia Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Tenosynovitis Drugs Market

• 14.1. South Korea Tenosynovitis Drugs Market Overview
• 14.2. South Korea Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Tenosynovitis Drugs Market

• 15.1. Western Europe Tenosynovitis Drugs Market Overview
• 15.2. Western Europe Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Tenosynovitis Drugs Market

• 16.1. UK Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Tenosynovitis Drugs Market

• 17.1. Germany Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Tenosynovitis Drugs Market

• 18.1. France Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Tenosynovitis Drugs Market

• 19.1. Italy Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Tenosynovitis Drugs Market

• 20.1. Spain Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Tenosynovitis Drugs Market

• 21.1. Eastern Europe Tenosynovitis Drugs Market Overview
• 21.2. Eastern Europe Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Tenosynovitis Drugs Market

• 22.1. Russia Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Tenosynovitis Drugs Market

• 23.1. North America Tenosynovitis Drugs Market Overview
• 23.2. North America Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Tenosynovitis Drugs Market

• 24.1. USA Tenosynovitis Drugs Market Overview
• 24.2. USA Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Tenosynovitis Drugs Market

• 25.1. Canada Tenosynovitis Drugs Market Overview
• 25.2. Canada Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Tenosynovitis Drugs Market

• 26.1. South America Tenosynovitis Drugs Market Overview
• 26.2. South America Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Tenosynovitis Drugs Market

• 27.1. Brazil Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Tenosynovitis Drugs Market

• 28.1. Middle East Tenosynovitis Drugs Market Overview
• 28.2. Middle East Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Tenosynovitis Drugs Market

• 29.1. Africa Tenosynovitis Drugs Market Overview
• 29.2. Africa Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Tenosynovitis Drugs Market Competitive Landscape And Company Profiles

• 30.1. Tenosynovitis Drugs Market Competitive Landscape
• 30.2. Tenosynovitis Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Tenosynovitis Drugs Market Other Major And Innovative Companies

• 31.1. GSK plc
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Eli Lilly and Company
• 31.4. Amgen Inc.
• 31.5. Teva Pharmaceutical Industries Ltd.
• 31.6. Sun Pharmaceutical Industries Ltd.
• 31.7. Perrigo Company plc
• 31.8. Cipla Limited
• 31.9. Dr. Reddy's Laboratories Ltd.
• 31.10. Aurobindo Pharma Limited
• 31.11. Endo International plc
• 31.12. Lupin Limited
• 31.13. Mallinckrodt Pharmaceuticals
• 31.14. Zydus Cadila Healthcare
• 31.15. AdvaCare Pharma

32. Global Tenosynovitis Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Tenosynovitis Drugs Market

34. Recent Developments In The Tenosynovitis Drugs Market

35. Tenosynovitis Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Tenosynovitis Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Tenosynovitis Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Tenosynovitis Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer